HC Wainwright Reaffirms Buy Rating for ImmunoPrecise Antibodies (NASDAQ:IPA)

HC Wainwright reissued their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

ImmunoPrecise Antibodies Stock Performance

IPA opened at $0.38 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.01 and a debt-to-equity ratio of 0.36. The company has a market cap of $11.96 million, a price-to-earnings ratio of -0.49 and a beta of 0.09. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $1.64. The firm’s fifty day simple moving average is $0.46 and its two-hundred day simple moving average is $0.49.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC lifted its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the period. Ingalls & Snyder LLC owned approximately 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.